Novan Provides Update on SB204 Development Program
March 06, 2017 06:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302...
Novan Announces SB204 Program Update Conference Call and Webcast
March 03, 2017 16:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Monday, Mar. 6, at 8 a.m....
Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting
March 02, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the...
Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
March 01, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 01, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that preclinical data demonstrating the anti-viral effects of the Company’s...
Novan Licenses SB204 to Sato for Acne in Japan
January 17, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has entered into an exclusive license agreement with Sato...
Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
November 29, 2016 06:05 ET
|
Novan, Inc.
Number of Patients with Complete Clearance of Genital Warts Provides Clinical Evidence of Nitric Oxide Anti-Viral Activity Against HPV Company Plans End-of-Phase 2 Meeting for First Half of...
Novan to Present at Piper Jaffray 28th Annual Healthcare Conference
November 23, 2016 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that Nathan Stasko, PhD, President and Chief Executive Officer of Novan,...
Novan Announces Preclinical Data Demonstrating Immunomodulatory Effect In Vivo
November 16, 2016 09:05 ET
|
Novan, Inc.
Topical Application of SB414 Inhibited IL-17 in Psoriasis Mouse Model Effect Relates to Multiple Inflammatory Skin Diseases MORRISVILLE, N.C., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the...